Wells Fargo & Company Apellis Pharmaceuticals, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
303Shares Held
113MCall Options Held
5.21MPut Options Held
691K-
Wellington Management Group LLP Boston, MA16.4MShares$491 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$348 Million15.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$333 Million5.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$294 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$174 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.29B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...